Greater Biosynthetic Liver Dysfunction in Primary Sclerosing Cholangitis Suggests Co-existent or Impending Cholangiocarcinoma.

about

Greater Biosynthetic Liver Dysfunction in Primary Sclerosing Cholangitis Suggests Co-existent or Impending Cholangiocarcinoma.

Item

http://www.wikidata.org/entity/Q38798747

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Greater Biosynthetic Liver Dys ...... Impending Cholangiocarcinoma.

@en

type

Item

label

Greater Biosynthetic Liver Dys ...... Impending Cholangiocarcinoma.

@en

prefLabel

Greater Biosynthetic Liver Dys ...... Impending Cholangiocarcinoma.

@en

P1476

Greater Biosynthetic Liver Dys ...... Impending Cholangiocarcinoma.

@en

P2093

Abhishek Agnihotri

http://www.w3.org/2001/XMLSchema#string

Ahmet Gurakar

http://www.w3.org/2001/XMLSchema#string

Enver Ucbilek

http://www.w3.org/2001/XMLSchema#string

Panagiotis Trilianos

http://www.w3.org/2001/XMLSchema#string

P2860

Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis.

p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.

Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.

Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.

A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.

Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.

Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.

Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

P304

1-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14218/JCTH.2015.00048

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27047765

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

cholangitis

P932

4807136

http://www.w3.org/2001/XMLSchema#string